Monogenic hypercholesterolemias: New genes, new drug targets

Russian Journal of Genetics

Volumn 44, Issue 10, 2008, Pages 1134-1140

  Mandelshtam, M Y ^a   Vasilyev, V B ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

EID: 54049132876     PISSN: 10227954     EISSN: 16083369     Source Type: Journal    
DOI: 10.1134/S1022795408100025     Document Type: Review

References (39)

1. Goldstein, J.L, Hobbs, H.H, and Brown, M.S, Familial Hypercholesterolemia, The Metabolic and Molecular Basis of Inherited Disease, Scriver, C.R., Beudet, A.L., Sly, W.S., and Valle, D., Eds., New York: McGrew Hill, 2001, vol. III, pp. 2863-2914.
2. J.L. Goldstein M.S. Brown 2001 Molecular Medicine: The Cholesterol Quartet Science 292 1310 1312
3. T.L. Innerarity R.W. Mahley K.H. Weisgraber 1990 Familial Defective Apolipoprotein B-100: A Mutation of Apolipoprotein B That Causes Hypercholesterolemia Lipid Res. 31 1337 1349
4. P.S. Hansen 1998 Familial Defective Apolipoprotein B-100 Dan. Med. Bull. 45 4 370 382
5. F.M. Zakharova Yu.A. Tatishcheva V.I. Golubkov 2007 Familial Hypercholesterolemia in St. Petersburg: Diversity of Mutations Argues against a Strong Founder Effect Russ. J. Genet. 43 9 1046 1052
6. C.K. Garcia K. Wilund M. Arca 2001 Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein Science 292 1394 1398
7. M. Arca G. Zuliani K. Wilund 2002 Autosomal Recessive Hypercholesterolemia in Sardinia, Italy, and Mutations in ARH: A Clinical and Molecular Genetic Analysis Lancet 359 841 847
8. N.G. Seidah S. Benjannet L. Wickham 2003 The Secretory Proprotein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation Proc. Natl. Acad. Sci. USA 100 3 928 933
9. M. Abifadel M. Varret J.P. Rabès 2003 Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia Nat. Genet. 34 2 154 156
10. D. Lopez 2008 PCSK9: An Enigmatic Protease Biochim. Biophys. Acta 1781 4 184 191
11. I.K. Kotowski A. Pertsemlidis A. Luke 2006 A Spectrum of PCKS9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol Am. J. Hum. Genet. 78 410 422
12. J. Cohen A. Pertsemlidis I.K. Kotowski 2005 Low LDL Cholesterol in Individuals of African Descent Resulting from Frequent Nonsense Mutations in PCSK9 Nat. Genet. 37 2 161 165
13. J.D. Horton J.C. Cohen H.H. Hobbs 2007 Molecular Biology of PCSK9: Its Role in LDL Metabolism Trends Biochem. Sci. 32 2 71 77
14. M.Yu. Mandelshtam 2003 What Has Familial Hypercholesterolemia Study Contributed towards the Understanding of Dislipidemia Genetics? Med. Genet. 2 12 509 519
15. J.L. Goldstein J.A. Helgeson M.S. Brown 1979 Inhibition of Cholesterol Synthesis with Compactin Renders Growth of Cultured Cells Dependent on the Low Density Lipoprotein Receptor J. Biol. Chem. 254 12 5403 5409
16. M. Van Heek C. France D.S. Compton 1997 In Vivo Mechanism-Based Discovery of a Potent Cholesterol Absorption Inhibitor (SCH 58235) through the Identifications of the Active Metabolites of SCH48461 J. Pharmacol. Exptl. Ther. 283 157 163
17. S.W. Altmann H.R. Davis L. Zhu 2004 Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption Science 303 1201 1204
18. H.R. Davis E.P. Veltri 2007 Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to Reduce Intestinal Cholesterol Absorption and Treat Hyperlipidemia J. Atheroscler. Thromb. 14 3 99 108
19. M.E. Sweeney R.R. Johnson 2007 Ezetimibe: An Update on the Mechanism of Action, Pharmacokinetics and Recent Clinical Trials Expert Opin. Drug. Metab. Toxicol. 3 3 441 450
20. S.C. Hunt P.N. Hopkins K. Bulka 2000 Genetic Localization to Chromosome 1p32 of the Third Locus for Familial Hypercholesterolemia in a Utah Kindred Arterioscler. Thromb. Vasc. Biol. 20 1089 1093
21. S. Benjannet D. Rhainds R. Essalmani 2004 NARC-1/PCSK9 and Its Natural Mutants: Zymogen Cleavage and Effects on the Low Density Lipoprotein (LDL) Receptor and LDL Cholesterol J. Biol. Chem. 279 47 48865 48875
22. K.N. Maxwell J.L. Breslow 2004 Adenoviral-Mediated Expression of Pcsk9 in Mice Results in a Low-Density Lipoprotein Receptor Knockout Phenotype Proc. Natl. Acad. Sci. USA 101 18 7100 7105
23. S.W. Park Y.A. Moon J.D. Horton 2004 Post-Transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver J. Biol. Chem. 279 48 50630 50638
24. J.C. Cohen E. Boerwinkle T.H. Mosley H.H. Hobbs 2006 Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease N. Engl. J. Med. 354 12 1264 1272
25. S. Rashid D.E. Curtis R. Garuti 2005 Decreased Plasma Cholesterol and Hypersensitivity to Statins in Mice Lacking Pcsk9 Proc. Natl. Acad. Sci. USA 102 15 5374 5379
26. K.N. Maxwell E.A. Fisher J.L. Breslow 2005 Overexpression of PCSK9 Accelerates the Degradation of the LDLR in a Post-Endoplasmic Reticulum Compartment Proc. Natl. Acad. Sci. USA 102 6 2069 2074
27. J. Cameron L. Holla T. Ranheim 2006 Effect of Mutations in the PCSK9 Gene on the Cell Surface LDL Receptors Hum. Mol. Genet. 15 9 1551 1558
28. T.A. Lagace D.E. Curtis R. Garuti 2006 Secreted PCSK9 Decreases the Number of LDL Receptors in Hepatocytes and in Livers of Parabiotic Mice J. Clin. Invest. 116 11 2995 3005
29. M.C. McNutt T.A. Lagace J.D. Horton 2007 Catalytic Activity Is not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells J. Biol. Chem. 282 20799 20803
30. S. Poirier A. Prat E. Marcinkiewicz 2006 Implication of the Proprotein Convertase NARC-1/PCSK9 in the Development of the Nervous System J. Neurochem. 98 3 838 850
31. Z. Zhao Y. Tuakli-Wosornu T.A. Lagace 2006 Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote Am. J. Hum. Genet. 79 3 514 523
32. A.J. Hooper A.D. Marais D.M. Tanyanyiwa J.R. Burnett 2007 The C679X Mutation in PCSK9 Is Present and Lowers Blood Cholesterol in a Southern African Population Atherosclerosis 193 2 445 448
33. G. Dubuc A. Chamberland H. Wassef 2004 Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia, Arterioscler Thromb. Vasc. Biol. 24 8 1454 1459
34. H.J. Jeong H.S. Lee K.S. Kim 2008 Sterol-Dependent Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 Expression by Sterol-Regulatory Element Binding Protein-2 J. Lipid Res. 49 2 399 409
35. S. Kourimate C. Le May C. Langhi 2008 Dual Mechanisms for the Fibrate-Mediated Repression of Proprotein Convertasesubtilisin/Kexin Type 9 J. Biol. Chem. 283 15 9666 9673
36. D.E. Piper S. Jackson Q. Liu 2007 The Crystal Structure of PCSK9: A Regulator of Plasma LDL-Cholesterol Structure 15 5 545 552
37. E.N. Hampton M.W. Knuth J. Li 2007 The Self-Inhibited Structure of Full-Length PCSK9 at 1.9 Å Reveals Structural Homology with Resistin within the C-Terminal Domain Proc. Natl. Acad. Sci. USA 104 37 14604 14609
38. D. Fan P.G. Yancey S. Qiu 2008 Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity Biochemistry 47 6 1631 1639
39. H.J. Kwon T.A. Lagace M.C. McNutt 2008 Molecular Basis for LDL Receptor Recognition by PCSK9 Proc. Natl. Acad. Sci. USA 105 6 1820 1825